Indolent B-Cell Non-Hodgkin’s Lymphomas
December 01, 1997
The indolent lymphomas as a group remain an enigma for both clinicians and pathologists. These malignancies are among the most sensitive to low-dose oral alkylating agents, radiotherapy, and steroids. However, although the overwhelming majority of patients with advanced-stage indolent lymphomas achieve a very good partial remission, far fewer patients achieve lasting complete remission and few, if any, are cured using conventional aggressive combination chemotherapy. This dichotomy between sensitivity to treatment on the one hand, yet incurability on the other has transformed the indolent lymphomas into an area of extremely active research at both the basic molecular level and in clinical trials.